Castagnetti, F
Gugliotta, G
Breccia, M
Stagno, F
Iurlo, A
Albano, F
Abruzzese, E
Martino, B
Levato, L
Intermesoli, T
Pregno, P
Rossi, G
Gherlinzoni, F
Leoni, P
Cavazzini, F
Venturi, C
Soverini, S
Testoni, N
Alimena, G
Cavo, M
Martinelli, G
Pane, F
Saglio, G
Rosti, G
Baccarani, M
,
Article History
Received: 22 April 2015
Revised: 20 May 2015
Accepted: 29 May 2015
First Online: 19 June 2015
Competing interests
: FC has acted as a consultant for and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and ARIAD; GG has acted as a consultant and received honoraria from Novartis and Bristol-Myers Squibb; M Breccia has acted as a consultant for Bristol-Myers Squibb and Novartis, Pfizer, Ariad; EA has acted as a consultant for Novartis and Bristol-Myers Squibb; GM served on the speakers’ bureaus of Novartis, Bristol-Myers Squibb and Pfizer; GR has acted as a consultant for and received honoraria from Novartis; FP received research support from Novartis, served as advisor for Novartis, Bristol-Myers Squibb and ARIAD Pharmaceuticals, and received lecture fees from Novartis and Bristol-Myers Squibb; GS has acted as a consultant for and received honoraria from Bristol-Myers Squibb, Novartis, ARIAD Pharmaceuticals and Celgene; G Rosti has acted as a consultant for Novartis, Bristol-Myers Squibb and ARIAD Pharmaceuticals and served on the speakers’ bureaus of Novartis, Bristol-Myers Squibb and Roche; M Baccarani received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and ARIAD Pharmaceuticals and served on the speakers’ bureaus of Novartis and Bristol-Myers Squibb. The other authors declare no conflict of interest.